Drugs

, Volume 72, Issue 12, pp 1631–1643 | Cite as

Managing Post-Transplant Lymphoproliferative Disorders in Solid-Organ Transplant Recipients

A Review of Immunosuppressant Regimens
Review Article

Abstract

Post-transplant lymphoproliferative disorders (PTLD) are a heterogeneous group of potentially life-threatening complications that occur after solid organ and bone marrow transplantation. Risk factors for acquiring PTLD are type of organ transplanted, age, intensity of immunosuppression, viral infections such as Epstein-Barr virus (EBV) and time after transplantation. Due to a dearth of well designed prospective trials, treatment for PTLD is often empirical, with reduction in immunosuppression accepted as the first step. Rituximab, a monoclonal antibody directed against the CD20 antigen of immature B cells, is often used as monotherapy after reduction in immunosuppression, although this is associated with a high risk of relapse if patients have at least one of the following risk factors: age greater than 60 years, elevated lactate dehydrogenase levels and Eastern Cooperative Oncology Group Score between 2 and 4. For such patients, rituximab should be considered in combination with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone), particularly if high-grade PTLD is present.

Although widely prescribed, the use of ganciclovir for PTLD remains controversial as EBV-transformed cells lack the thymidine kinase necessary for ganciclovir activation. Newer antivirals that combine ganciclovir with activators of cellular thymidine kinase have shown promising results in preclinical studies. In the absence of controlled trials, surgery may be indicated for localized disease and radiotherapy for patients with impending spinal cord compression or disease localized to the central nervous system or orbit.

Future interventions may include adoptive immunotherapy, intravenous immunoglobulin, mammalian target of rapamycin inhibitors, monoclonal antibodies to interleukin-6 and galectin-1, and even EBV vaccination. Although several trials are in progress, it is necessary to wait for the long-term outcome of these studies on risk of PTLD relapse.

Notes

Acknowledgements

No sources of funding were used to prepare this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this article.

References

  1. 1.
    Starzl TE, Nalesnik MA, Porter KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984 Mar; 1 (8377): 583–7PubMedCrossRefGoogle Scholar
  2. 2.
    Végso G, Hajdu M, Sebestyén A. Lymphoproliferative disorders after solid organ transplantation-classification, incidence, risk factors, early detection and treatment options. Pathol Oncol Res 2011 Sep; 17 (3): 443–54PubMedCrossRefGoogle Scholar
  3. 3.
    Leblond V, Sutton L, Dorent R, et al. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. J Clin Oncol 1995 Apr; 13 (4): 961–8PubMedGoogle Scholar
  4. 4.
    Allen U, Hébert D, Moore D, et al. Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplant recipients, 1988–97: a Canadian multi-centre experience. Canadian PTLD Survey Group — 1998. Pediatr Transplant 2001 Jun; 5 (3): 198–203Google Scholar
  5. 5.
    Mucha K, Foroncewicz B, Ziarkiewicz-Wroblewska B, et al. Post-transplant lymphoproliferaive disorder in view of the new WHO classification: a more rational approach to a protean disease?. Nephrol Dial Translant 2010; 25: 2089–98CrossRefGoogle Scholar
  6. 6.
    Allen U, Preiksaitis J. Epstein-Barr virus and post-transplant lymphoproliferative disorder in solid organ transplant recipients. Am J Transplant 2009; 9 Suppl. 4: S87–96PubMedCrossRefGoogle Scholar
  7. 7.
    McLaughlin K, Wajstaub S, Marotta P, et al. Increased risk for posttransplant lymphoproliferative disease in recipients of liver transplants with hepatitis C. Liver Transpl 2000; 6: 570–4PubMedCrossRefGoogle Scholar
  8. 8.
    Opelz G, Dohler B. Lymphomas after solid organ trans-plantation: a collaborative transplant study report. Am J Transplant 2003; 4: 222–30CrossRefGoogle Scholar
  9. 9.
    Opelz G. Döhler Impact of HLA mismatching on incidence of osttransplant non-hodgkin lymphoma after kidney transplantation. Transplantation 2010 Mar; 89 (5): 567–72PubMedCrossRefGoogle Scholar
  10. 10.
    Nourse JP, Jones K, Gandhi MK. Epstein-Barr virus related post-transplant lymphoproliferative disorders:pathogenetic insights into targeted therapy. Am J Transplant 2011; 11: 888–95PubMedCrossRefGoogle Scholar
  11. 11.
    Boubenider S, Hiesse C, Groupy C, et al. Incidence and consequences of post-transplantation lymphoproliferative disorders. J Nephrol 1997; 10: 136–45PubMedGoogle Scholar
  12. 12.
    Opelz G, Henderson R. Incidence of non-Hodgkin lym-phoma in kidney and heart transplant recipients. Lancet 1993; 342 (8886–7): 1514–6PubMedCrossRefGoogle Scholar
  13. 13.
    Younes BS, McDiarmid SV, Martin MG, et al. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. Transplantation 2000; 70: 94–9PubMedGoogle Scholar
  14. 14.
    Cao S, Cox KL, Berquist W, et al. Long-term outcomes in pediatric liver recipients: comparison between cyclospirin A and tacrolimus. Pediatr Transplant 1999; 3: 22–6PubMedCrossRefGoogle Scholar
  15. 15.
    Taylor AL, Marcus R, Bradley JA. Post-transplant lym-phoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol 2005; 56: 155–67PubMedCrossRefGoogle Scholar
  16. 16.
    Cockfield SM, Preiksaitis J, Harvey E, et al. Is sequential use of ALG and OKT3 in renal transplants associated with an increased incidence of fulminant posttransplant lymphoproliferative disorder?. Transplant Proc 1991; 23: 1106–7PubMedGoogle Scholar
  17. 17.
    Caillard S, Dharnidharka V, Agodoa L, et al. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005; 80: 1233–43PubMedCrossRefGoogle Scholar
  18. 18.
    Kirk AD, Cherikh WS, Ring M, et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant 2007; 7: 2619–25PubMedCrossRefGoogle Scholar
  19. 19.
    Kahan BD, Yakupoglu YK, Schoenberg L, et al. Low in-cidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation 2005; 80: 749–58PubMedCrossRefGoogle Scholar
  20. 20.
    Kahan BD, Knight R, Schoenberg L, et al. Ten years of sirolimus therapy for human renal transplantation: the University of Texas at Houston experience. Transplant Proc 2003; 35: 25S-34SCrossRefGoogle Scholar
  21. 21.
    Yakupoglu YK, Buell JF, Woodle S, et al. Individualization of immunosuppressive therapy. III. Sirolimus associated with a reduced incidence of malignancy. Transplant Proc 2006; 38: 358–61Google Scholar
  22. 22.
    DiNardo CD, Tsai DE. Treatment advances in post-transplant lymphoproliferative disease. Curr Opin Hematol 2010; 17: 368–74PubMedCrossRefGoogle Scholar
  23. 23.
    O’Neill JO, Edwards LB, Taylor DO. Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25: 1186–91PubMedCrossRefGoogle Scholar
  24. 24.
    Robson R, Cecka JM, Opelz G, et al. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant 2005; 5: 2954–60PubMedCrossRefGoogle Scholar
  25. 25.
    Funch DP, Ko HH, Travasso J, et al. Posttransplant lym-phoproliferative disorder among renal transplant patients in relation to the use of mycophenolate mofetil. Transplantation 2005; 80: 1174–80PubMedCrossRefGoogle Scholar
  26. 26.
    Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010; 10: 547–57PubMedCrossRefGoogle Scholar
  27. 27.
    Pascual J. Post-transplant lymphoproliferative disorder: the potential of proliferation signal inhibitors. Nephrol Dial Transplant 2007; 22: 27–35CrossRefGoogle Scholar
  28. 28.
    Saueressig MG, Boussaud V, Amrein C, et al. Risk factors for post-transplant lymphoproliferative disease in patients with cystic fibrosis. Clin Transplant 2011; 25: E430–6PubMedCrossRefGoogle Scholar
  29. 29.
    Parker A, Bowles K, Bradley JA, et al. Diagnosis of post-transplant lymphoproliferative disorders in solid organ transplant recipients: BCSH and BTS guidelines. Br J Hematol 2010; 149: 675–92CrossRefGoogle Scholar
  30. 30.
    Harris NL, Ferry JA, Swerdlow SH. Posttransplant lympho-proliferative disorders: summary of Society for Hematopathology Workshop. Semin Diagn Pathol 1997; 14: 8–14PubMedGoogle Scholar
  31. 31.
    Gulley ML, Tang W. Laboratory assays for Epstein-Barr virus-related disease. J Mol Diagn 2008 Jul; 10 (4): 279–92PubMedCrossRefGoogle Scholar
  32. 32.
    Gulley ML, Tang W. Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproli-ferative disorder. Clin Microbiol Rev 2010 Apr; 23 (2): 350–66PubMedCrossRefGoogle Scholar
  33. 33.
    Tsao L, Hsi ED. The clinicopathologic spectrum of post-transplantation lymphoproliferative disorders. Arch Pathol Lab Med 2007 Aug; 131 (8): 1209–18PubMedGoogle Scholar
  34. 34.
    Cesarman E, Chadburn A, Liu YF, et al. BCL-6 gene mu-tations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome. Blood 1998; 92: 2294–302PubMedGoogle Scholar
  35. 35.
    Nelson NP, Nalesnik MA, Bahler DW, et al. Epstein-Barr virus-negative posttransplant lymphoproliferative disorders: a distinct entity?. Am J Surg Pathol 2000; 24: 375–85PubMedCrossRefGoogle Scholar
  36. 36.
    Parker A, Bowles K, Bradley JA, et al. Management of post-transplant lymphoproliferative disorders in solid organ transplant recipients: BCSH and BTS guidelines. Br J Hematol 2010; 149: 693–705CrossRefGoogle Scholar
  37. 37.
    Vounes A, Samad N. Utility of mTOR inhibition in he-matologic malignancies. Oncologist 2011; 16 (6): 730–41CrossRefGoogle Scholar
  38. 38.
    El-Salem M, Raghunath PN, Marzec M, et al. Constitutive activation of mTOR signaling pathway in post-transplant lymphoproliferative disorders. Lab Invest 2007 Jan; 87 (1): 29–39PubMedCrossRefGoogle Scholar
  39. 39.
    Mathew T, Kreis H, Friend P. Two-year incidence of ma-lignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 2004 Aug; 18 (4): 446–9PubMedCrossRefGoogle Scholar
  40. 40.
    Campistol JM, Eris J, Oberbauer R, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006 Feb; 17 (2): 581–9PubMedCrossRefGoogle Scholar
  41. 41.
    McDonald RA, Smith JM, Ho M, et al. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant 2008 May; 8 (5): 984–9PubMedCrossRefGoogle Scholar
  42. 42.
    Krams SM, Martinez OM. Epstein-Barr virus, rapamycin, and host immune responses. Curr Opin Organ Transplant 2008 Dec; 13 (6): 563–8PubMedCrossRefGoogle Scholar
  43. 43.
    Iaria G, Anselmo A, De Luca L, et al. Conversion to ra-pamycin immunosuppression for malignancy after kidney transplantation: case reports. Transplant Proc 2007 Jul–Aug; 39 (6): 2036–7PubMedCrossRefGoogle Scholar
  44. 44.
    Cullis B, D’Souza R, McCullagh P, et al. Sirolimus-induced remission of posttransplantation lymphoproliferative disorder. Am J Kidney Dis 2006 May; 47 (5): 67–72CrossRefGoogle Scholar
  45. 45.
    Boratynska M, Watorek E, Smolska D, et al. Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies. Transplant Proc 2007 Nov; 39 (9): 2736–9PubMedCrossRefGoogle Scholar
  46. 46.
    Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003 Aug; 349 (9): 847–58PubMedCrossRefGoogle Scholar
  47. 47.
    Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005 Aug; 23 (23): 5347–56PubMedCrossRefGoogle Scholar
  48. 48.
    Nee R, Hurst FP, Dharnidharka VR, et al. Racial variation in the development of posttransplant lymphoproliferative disorders after renal transplantation. Transplantation 2011 Jul; 92 (2): 190–5PubMedCrossRefGoogle Scholar
  49. 49.
    Sampaio MS, Cho YW, Shah T, et al. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients. Transplantation 2012 Jan; 93 (1): 73–81PubMedCrossRefGoogle Scholar
  50. 50.
    Braconnier P, Del Marmol V, Broeders N, et al. Combined introduction of anti-IL2 receptor antibodies, mycophenolic acid and tacrolimus: effect on malignancies after renal transplantation in a single-centre retrospective cohort study. Nephrol Dial Transplant 2012 Jun; 27 (6): 2547–53PubMedCrossRefGoogle Scholar
  51. 51.
    Campbell P, Marcus R. Monoclonal antibody therapy for lymphoma. Blood Rev 2003 Sep; 17 (3): 143–52PubMedCrossRefGoogle Scholar
  52. 52.
    Weiner GJ. Rituximab: mechanism of action. Semin He-matol 2010 Apr; 47 (2): 115–23CrossRefGoogle Scholar
  53. 53.
    Carbone A, Gloghini A, Dotti G. EBV-associated lympho-proliferative disorders: classification and treatment. Oncologist 2008 May; 13 (5): 577–85PubMedCrossRefGoogle Scholar
  54. 54.
    Ohta H, Fukushima N, Ozono K. Pediatric post-transplant lymphoproliferative disorder after cardiac transplantation. Int J Hematol 2009 Sep; 90 (2): 127–36PubMedCrossRefGoogle Scholar
  55. 55.
    Cook RC, Connors JM, Gascoyne RD, et al. Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation. Lancet 1999 Nov; 354 (9191): 1698–9PubMedCrossRefGoogle Scholar
  56. 56.
    Oertel SH, Anagnostopoulos I, Bechstein WO, et al. Treatment of posttransplant lymphoproliferative disorder with the anti-CD20 monoclonal antibody rituximab alone in an adult after liver transplantation: a new drug in therapy of patients with posttransplant lymphoproliferative disorder after solid organ transplantation?. Transplantation 2000 Feb; 69 (3): 430–2PubMedCrossRefGoogle Scholar
  57. 57.
    Zilz ND, Olson LJ, McGregor CG. Treatment of post-transplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplantation. J Heart Lung Transplant 2001 Jul; 20 (7): 770–2PubMedCrossRefGoogle Scholar
  58. 58.
    Berney T, Delis S, Kato T, et al. AG. Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients. Transplantation 2002 Oct; 74 (7): 1000–6Google Scholar
  59. 59.
    Pham PT, Wilkinson AH, Gritsch HA, et al. Monotherapy with the anti-CD20 monoclonal antibody rituximab in a kidney transplant recipient with posttransplant lymphoproliferative disease. Transplant Proc 2002 Jun; 34 (4): 1178–81PubMedCrossRefGoogle Scholar
  60. 60.
    Milpied N, Vasseur B, Parquet N, et al. Humanized anti-CD20 monoclonal antibody (rituximab) in post transplant B- lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000; 11 Suppl. 1: 113–6PubMedCrossRefGoogle Scholar
  61. 61.
    Ganne V, Siddiqi N, Kamplath B, et al. Humanized anti-CD20 monoclonal antibody (rituximab) treatment for post- transplant lymphoproliferative disorder. Clin Transplant 2003 Oct; 17 (5): 417–22PubMedCrossRefGoogle Scholar
  62. 62.
    Heslop HE, Savoldo B, Rooney CM. Cellular therapy of Epstein-Barr-virus-associated post-transplant lympho-proliferative disease. Best Pract Res Clin Haematol 2004 Sep; 17 (3): 401–13PubMedCrossRefGoogle Scholar
  63. 63.
    Hirokawa M, Kawabata Y, Fujishima N, et al. Prolonged reactivation of cytomegalovirus infection following successful rituximab therapy for Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder. Int J Hematol 2007 Oct; 86 (3): 291–2PubMedCrossRefGoogle Scholar
  64. 64.
    Imashuku S, Teramura T, Morimoto A, et al. Prolonged hypogammaglobulinemia following rituximab treatment for post transplant Epstein-Barr virus-associated lymphoproli-ferative disease. Bone Marrow Transplant 2004; 33: 129–30PubMedCrossRefGoogle Scholar
  65. 65.
    Irie E, Shirota Y, Suzuki et al. Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis. Intl J Hematol 2010 Apr; 91 (3): 501–8CrossRefGoogle Scholar
  66. 66.
    Savoldo B, Rooney CM, Quiros-Tejeira RE, et al. Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am J Transplant 2005 Mar; 5 (3): 566–72PubMedCrossRefGoogle Scholar
  67. 67.
    Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006 Apr; 107 (8): 3053–7PubMedCrossRefGoogle Scholar
  68. 68.
    Dotti G, Rambaldi A, Fiocchi R, et al. Anti-CD20 antibody (rituximab) administration in patients with late occurring lymphomas after solid organ transplant. Haematologica 2001 Jun; 86 (6): 618–23PubMedGoogle Scholar
  69. 69.
    Oertel SH, Verschuuren E, Reinke P, et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 2005 Dec; 5 (12): 2901–6PubMedCrossRefGoogle Scholar
  70. 70.
    Choquet S, Oertel S, LeBlond V, et al. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution. Ann Hematol 2007 Aug; 86 (8): 599–607PubMedCrossRefGoogle Scholar
  71. 71.
    Coiffier B. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin’s lymphoma. Semin Oncol 2002 Apr; 29 (2 Suppl. 6): 18–22PubMedCrossRefGoogle Scholar
  72. 72.
    Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2005 Jun; 23 (18): 4117–26PubMedCrossRefGoogle Scholar
  73. 73.
    Pfreundschuh M, Ho AD, Cavallin-Stahl E, et al., Mab-Thera International Trial (MInT) Group. Prognostic sig-nificance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the Mab-Thera International Trial Group (MInT) study. Lancet Oncol 2008 May; 9 (5): 435–44PubMedCrossRefGoogle Scholar
  74. 74.
    Jain AB, Marcos A, Pokharna R, et al. Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center. Transplantation 2005 Dec; 80 (12): 1692–8PubMedCrossRefGoogle Scholar
  75. 75.
    Elstrom RL, Andreadis C, Aqui NA, et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 2006 Mar; 6 (3): 569–76PubMedCrossRefGoogle Scholar
  76. 76.
    Taylor AL, Bowles KM, Callaghan CJ, et al. Anthracycline-based chemotherapy as first-line treatment in adults with malignant posttransplant lymphoproliferative dis-order after solid organ transplantation. Transplantation 2006 Aug; 82 (3): 375–81PubMedCrossRefGoogle Scholar
  77. 77.
    Buadi FK, Heyman MR, Gocke CD, et al. Treatment and outcomes of post-transplant lymphoproliferative disease: a single institution study. Am J Hematol 2007 Mar; 82 (3): 208–14PubMedCrossRefGoogle Scholar
  78. 78.
    Rodriguez-Abreu D, Filho VB, Zucca E. Peripheral T cell lymphomas unspecified (or not otherwise specified): a review. Hematol Oncol 2008; 26: 8–20PubMedCrossRefGoogle Scholar
  79. 79.
    Evens AM, David KA, Helenowski I, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol 2010 Feb; 28 (6): 1038–46PubMedCrossRefGoogle Scholar
  80. 80.
    Trappe R, Oertel S, Leblond V, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 2012; 13 (2): 196–206PubMedCrossRefGoogle Scholar
  81. 81.
    Trappe R, Hinrichs C, Appel U, et al. Treatment of PTLD with rituximab and CHOP reduces the risk of renal graft impairment after reduction of immunosuppression. Am J Transplant 2009 Oct; 9 (10): 2331–7PubMedCrossRefGoogle Scholar
  82. 82.
    Cavaliere R, Petroni G, Lopes MB, et al. Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Cancer 2010 Feb; 116 (4): 863–70PubMedCrossRefGoogle Scholar
  83. 83.
    Nabors LB, Palmer CA, Julian BA, et al. Isolated central nervous system posttransplant lymphoproliferative disorder treated with high-dose intravenous methotrexate. Am J Transplant 2009 May; 9 (5): 1243–8PubMedCrossRefGoogle Scholar
  84. 84.
    Funch DP, Walker AM, Schneider G, et al. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 2005 Dec; 5 (12): 2894–9000PubMedCrossRefGoogle Scholar
  85. 85.
    Williams SL, Hartline CB, Kushner NL, et al. In vitro ac-tivities of benzimidazole D- and L-ribonucleosides against herpesviruses. Antimicrob Agents Chemother 2003 Jul; 47 (7): 2186–92PubMedCrossRefGoogle Scholar
  86. 86.
    Mentzer SJ, Fingeroth J, Reilly JJ, et al. Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma. Blood Cells Mol Dis 1998 Jun; 24 (2): 114–23PubMedCrossRefGoogle Scholar
  87. 87.
    Perrine SP, Hermine Small T, et al. A phase I/II trial of arginine butyrate and ganciclovir in patients with Epstein-Barr-virus-associated lymphoid malignancies. Blood 2007 Mar; 109 (6): 2571–8PubMedCrossRefGoogle Scholar
  88. 88.
    Aull MJ, Buell JF, Trofe J, et al. Experience with 274 cardiac transplant recipients with posttransplant lymphoproliferative disorder: a report from the Israel Penn International Transplant Tumor Registry. Transplantation 2004 Dec; 78 (11): 1676–82PubMedCrossRefGoogle Scholar
  89. 89.
    Bates WD, Gray DW, Dada MA, et al. Lymphoproliferative disorders in Oxford renal transplant recipients. J Clin Pathol 2003 Jun; 56 (6): 439–46PubMedCrossRefGoogle Scholar
  90. 90.
    Reams BD, McAdams HP, Howell DN, et al. Posttransplant lymphoproliferative disorder: incidence, presentation, and response to treatment in lung transplant recipients. Chest 2003 Oct; 124 (4): 1242–9PubMedCrossRefGoogle Scholar
  91. 91.
    Dotti G, Fiocchi R, Motta T, et al. Lymphomas occurring late after solid-organ transplantation: influence of treatment on the clinical outcome. Transplantation 2002 Oct; 74 (8): 1095–102PubMedCrossRefGoogle Scholar
  92. 92.
    Douglas RS, Goldstein SM, Katowitz JA, et al. Orbital presentation of posttransplantation lymphoproliferative disorder: a small case series. Ophthalmology 2002 Dec; 109 (12): 2351–5PubMedCrossRefGoogle Scholar
  93. 93.
    Buell JF, Gross TG, Hanaway MJ, et al. Posttransplant lymphoproliferative disorder: significance of central nervous system involvement. Transplant Proc 2005 Mar; 37 (2): 954–5PubMedCrossRefGoogle Scholar
  94. 94.
    Kwong YL, Lam CC, Chan TM. Post-transplantation lymphoproliferative disease of natural killer cell lineage: a clinicopathological and molecular analysis. Br J Haematol 2000 Jul; 110 (1): 197–202PubMedCrossRefGoogle Scholar
  95. 95.
    Kwong YL. Natural killer-cell malignancies: diagnosis and treatment. Leukemia 2005 Dec; 19 (12): 2186–94PubMedCrossRefGoogle Scholar
  96. 96.
    Hsi ED, Singleton TP, Swinnen L, et al. S. Mucosa-associated lymphoid tissue-type lymphomas occurring in post-transplantation patients. Am J Surg Pathol 2000 Jan; 24 (1): 100–6Google Scholar
  97. 97.
    Aull MJ, Buell JF, Peddi VR, et al. MALToma: Helicobacter pylori-associated malignancy in transplant patients: a report from the Israel Penn International Transplant Tumor Registry with a review of published literature. Transplantation 2003 Jan; 75 (2): 225–8PubMedCrossRefGoogle Scholar
  98. 98.
    Kang SK, Kirkpatrick JP, Halperin EC. Low-dose radiation for posttransplant lymphoproliferative disorder. Am J Clin Oncol 2003 Apr; 26 (2): 210–4PubMedCrossRefGoogle Scholar
  99. 99.
    Comoli P, Maccario R, Locatelli F, et al. Treatment of EBV-related post-renal transplant lymphoproliferative disease with a tailored regimen including EBV-specific T cells. Am J Transplant 2005; 5: 1415–22PubMedCrossRefGoogle Scholar
  100. 100.
    Comoli P, Labirio M, Basso S, et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 2002 Apr; 99 (7): 2592–8PubMedCrossRefGoogle Scholar
  101. 101.
    Savoldo B, Goss JA, Hammer MM, et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 2006 Nov; 108 (9): 2942–9PubMedCrossRefGoogle Scholar
  102. 102.
    Haque T, Wilkie GM, Taylor C, et al. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 2002 Aug; 360 (9331): 436–42PubMedCrossRefGoogle Scholar
  103. 103.
    Haque T, Wilkie GM, Jones MM, et al. Allogeneic cyto-toxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multi-center clinical trial. Blood 2007 Aug; 110 (4): 1123–31PubMedCrossRefGoogle Scholar
  104. 104.
    Jones K, Nourse JP, Morrison L, et al. Expansion of EBNA1-specific effector T cells in posttransplantation lymphoproliferative disorders. Blood 2010 Sep; 116 (13): 2245–52PubMedCrossRefGoogle Scholar
  105. 105.
    Jenkins D, DiFrancesco L, Chaudhry A, et al. Successful treatment of post-transplant lymphoproliferative disorder in autologous blood stem cell transplant recipients. Bone Marrow Transplant 2002 Sep; 30 (5): 321–6PubMedCrossRefGoogle Scholar
  106. 106.
    Ouyang J, Juszczynski P, Rodig SJ, et al. Viral induction and targeted inhibition of galectin-1 in EBV+ post-transplant lymphoproliferative disorders. Blood 2011 Apr; 117 (16): 4315–22PubMedCrossRefGoogle Scholar
  107. 107.
    Haddad E, Paczesny S, Leblond V, et al. Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1–2 clinical trial. Blood 2001 Mar; 97 (6): 1590–7PubMedCrossRefGoogle Scholar
  108. 108.
    Gu SY, Huang TM, Ruan L, et al. First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. Dev Biol Stand 1995; 84: 171–7PubMedGoogle Scholar
  109. 109.
    Posfay-Barbe KM, Siegrist CA. Immunization and trans-plantation: what is new and what is coming?. Pediatr Transplant 2009 Jun; 13 (4): 404–10PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  1. 1.Department of MedicineCreighton University Medical CenterOmahaUSA
  2. 2.Division of Gastroenterology and Hepatology983285 Nebraska Medical CenterOmahaUSA

Personalised recommendations